Cite
HARVARD Citation
Cremer, P. et al. (2021). Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. pp. e410-e418. [Online].